About sage therapeutics - SAGE
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
SAGE At a Glance
SAGE Therapeutics, Inc.
55 Cambridge Parkway
Cambridge, Massachusetts 02142
| Phone | 1-617-299-8380 | Revenue | 41.24M | |
| Industry | Pharmaceuticals: Major | Net Income | -400,666,000.00 | |
| Sector | Health Technology | Employees | 353 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SAGE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.00 |
| Price to Book Ratio | 0.716 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.397 |
| Enterprise Value to Sales | -3.943 |
| Total Debt to Enterprise Value | -0.073 |
SAGE Efficiency
| Revenue/Employee | 116,835.694 |
| Income Per Employee | -1,135,031.161 |
| Receivables Turnover | 3.189 |
| Total Asset Turnover | 0.058 |
SAGE Liquidity
| Current Ratio | 7.419 |
| Quick Ratio | 7.419 |
| Cash Ratio | 7.043 |
SAGE Profitability
| Gross Margin | 74.602 |
| Operating Margin | -995.359 |
| Pretax Margin | -971.476 |
| Net Margin | -971.476 |
| Return on Assets | -56.057 |
| Return on Equity | -63.365 |
| Return on Total Capital | -84.01 |
| Return on Invested Capital | -62.843 |
SAGE Capital Structure
| Total Debt to Total Equity | 2.545 |
| Total Debt to Total Capital | 2.482 |
| Total Debt to Total Assets | 2.163 |
| Long-Term Debt to Equity | 2.262 |
| Long-Term Debt to Total Capital | 2.205 |